EGP is deployed in Ethereum Mainnet
EastGate Token
Creating solution to vital pharmaceutical problems by merging pharmacy with blockchain
Full transparency. More trust, Minimize risk, maximize rewards.
ABOUT EGP
EastGate Pharmaceuticals -
a dynamic biotech company
Eastgate Pharmaceuticals concentrates on altering the delivery pathways for well-known drugs, currently administered only by injections, to non-invasive (oral or sublingual) routes.
At the present time, the technology focuses on the delivery of insulin via a liquid insulin mouth solution based on proprietary composition, but it is believed that the technology may also be applicable to the delivery of other active pharmaceutical ingredients.
Eastgate Pharmaceuticals may also develop other novel formulations of pharmaceutical and natural products. Several biologically active existing molecules that address unmet needs of patients, especially those with ever-growing chronic conditions, have been identified.
The immediate objective of the project is to explore the development and advancement of the delivery technology in the MENA region and emerging markets in South East Asia. Eastgate/EGP has partnered with Daga International and its Pharmaceuticals division, ZenX FZE. The EGP project will operate as the Pharmaceuticals division. The goal is to foster partnerships including clinical, commercial and financial support.
AWESOME SERVICES
Business Model
Technology Platform
EastGate Pharmaceuticals Trade Secret proprietary technology is based on a self-nanoemulsifying drug delivery system
EGP Control Panel
Our secondary goal is to leverage our technology for the oral delivery of other active pharmaceutical ingredients for the treatment of non-diabetes indications
Blockchain
Blockchain technology is being incorporated by EastGate Pharmaceuticals to enhance transparency, security, and traceability in their operations
Research
EastGate Pharmaceuticals is pioneering research into non-invasive drug delivery methods, focusing on a liquid insulin mouth solution
STATISTIC DATA
EastGate Pharmaceuticals Token Holders
114
Ethereum Network
ABOUT ICO
Road Map
March 2022
Start of the ERC-20 Crypto Platform Development
April 2022
Start of the preparation for the ERC-20 Token Testing
August 2022
Deployment of EGP token on the Main Network
February 2023
Identify products that can be purchased with EGP tokens
August 2023
Collaboration with pharmaceutical stores to accept EGP token as payment
November 2024
Partnership with NULS and their Proof of Credit Mining (POCM) platform
December 2024
Launch Staked Coin Output (SCO) with NULS token
January 2025
List on exchange(s)
July 2025
Complete e-commerce website
January 2026
Launch of EastGate Blockchain
OUR DATA
Token Distribution
EGP Token (EastGate Pharmaceuticals)
Our Token Distribution model may change over time to reflect new business opportunities and our Token Burn Schedule.
- 57.5% Tradeable Tokens
- 8% Reserved Funding
- 15% Team and Founders
- 4% Board Advisors
- 7% Ecosystem Development
- 6% Marketing and Bounty
- 2.5% NULS Staked Coin Output (SCO)
- Name:EastGate Pharmaceuticals
- Type:ERC20
- Symbol:EGP
- Platform:Ethereum
- General release:100,000,000,000 EGP
General description
EGP token will be released on the basis of Ethereum platform and fully comply with ERC20* standard.
Support of this standard guarantees the compatibility of the token with third-party services (wallets, exchanges, listings, etc.), and provides easy integration.
DATA INFORMATION
Statistic Data
Holders
114
TRANSFERS (EGP)
196
ACCEPTED CURRENCY
10
+ CryptoExchanges
TBA
FAQ
Frequency Asked Questions
EGP Token price is TBA
Once complete, the EGP token can be used as a form of payment for pharmaceutical products and services.
OUR BRAIN
Management
Rose Perri
Chief Executive Officer
Rose C. Perri, President has held management and overseen operations for both private and public companies for the past 20+ years. She has served in a number of start-up biotech companies where her roles included those of principal shareholder, Senior Executive and Board Member. She, along with her late brother, E. Mark Perri, founded Biomin Therapeutics Corporation, a start-up biotech company, in 1990. Biomin was a publically-traded company both on the Toronto and Vancouver Stock Exchanges.
Bill Abajian
Chairman, President and Chief Operating Officer
Mr. William (Bill) D. Abajian brings over 30 years experience in the pharmaceutical and biotechnology industry. He started his career at Electro Nucleonics Inc. in Fairfield, New Jersey where he served as the Vice President of Sales and Marketing between 1981-1988. While at Electro Nucleonics he developed, manufactured and sold blood chemistry and diagnostic kits. Bill founded CPG Inc. in 1988 and served as its Chief Executive Officer until 2002. In 2004, he founded The Abajian Group LLC.
CONTACT US
Get in Touch
EGP Token - a division of ZENX FSE
Business Centre,Sharjah
Publishing City Free Zone, Sharjah,
United Arab Emirates
hello@egptokens.com
Stay connected:
